SK283342B6 - Použitie ribavirínu na prípravu farmaceutického prostriedku - Google Patents

Použitie ribavirínu na prípravu farmaceutického prostriedku Download PDF

Info

Publication number
SK283342B6
SK283342B6 SK1004-98A SK100498A SK283342B6 SK 283342 B6 SK283342 B6 SK 283342B6 SK 100498 A SK100498 A SK 100498A SK 283342 B6 SK283342 B6 SK 283342B6
Authority
SK
Slovakia
Prior art keywords
ribavirin
disease
cells
treatment
pharmaceutical composition
Prior art date
Application number
SK1004-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK100498A3 (en
Inventor
Robert Tam
Kandsamy Ramasamy
Devron Averett
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26712784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK283342(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/590,449 external-priority patent/US5767097A/en
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Publication of SK100498A3 publication Critical patent/SK100498A3/sk
Publication of SK283342B6 publication Critical patent/SK283342B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
SK1004-98A 1996-01-23 1997-01-21 Použitie ribavirínu na prípravu farmaceutického prostriedku SK283342B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/590,449 US5767097A (en) 1996-01-23 1996-01-23 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US3609497P 1997-01-17 1997-01-17
PCT/US1997/000600 WO1997026883A1 (en) 1996-01-23 1997-01-21 Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes

Publications (2)

Publication Number Publication Date
SK100498A3 SK100498A3 (en) 2001-03-12
SK283342B6 true SK283342B6 (sk) 2003-06-03

Family

ID=26712784

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1004-98A SK283342B6 (sk) 1996-01-23 1997-01-21 Použitie ribavirínu na prípravu farmaceutického prostriedku

Country Status (21)

Country Link
EP (1) EP0879056B1 (ru)
KR (1) KR100298158B1 (ru)
CN (1) CN1190198C (ru)
AT (1) ATE216886T1 (ru)
BR (1) BR9707154A (ru)
CA (1) CA2246162C (ru)
CZ (1) CZ293584B6 (ru)
DE (1) DE69712316T2 (ru)
DK (1) DK0879056T3 (ru)
ES (1) ES2172764T3 (ru)
HU (1) HU220105B (ru)
IL (1) IL125088A0 (ru)
NO (1) NO983372L (ru)
NZ (1) NZ330784A (ru)
PL (1) PL187439B1 (ru)
PT (1) PT879056E (ru)
RU (1) RU2186569C2 (ru)
SI (1) SI9720013A (ru)
SK (1) SK283342B6 (ru)
UA (1) UA46815C2 (ru)
WO (1) WO1997026883A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302474A1 (en) * 1996-10-16 2003-04-16 Ribapharm, Inc. Monocyclic L-nucleosides, analogs and uses thereof
KR100518903B1 (ko) 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Ｔｈ2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물
KR20020023939A (ko) * 1999-01-29 2002-03-29 와트 씨 데이빗, 해리 에이 루스제 리바비린에 의해 면역 반응을 조절하는 방법
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
WO2002014362A2 (en) * 2000-08-17 2002-02-21 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
MXPA05010419A (es) * 2003-03-28 2006-05-31 Pharmasset Inc Compuestos para el tratamiento de infecciones por flaviviridae.
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
RU2498813C2 (ru) * 2006-03-09 2013-11-20 Ом Фарма Иммуномодуляторные соединения и лечение заболеваний, связанных со сверхпродукцией воспалительных цитокинов
DK2032592T3 (da) 2006-06-12 2013-09-02 Cytos Biotechnology Ag Fremgangsmåder til pakning af oligonukleotider til virus-lignende partikler af rna-bakteriofager
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2861611B1 (en) 2012-05-25 2016-07-13 Janssen Sciences Ireland UC Uracyl spirooxetane nucleosides
WO2014100505A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
AU2015259053B2 (en) 2014-05-16 2020-12-24 Amgen Inc. Assay for detecting Th1 and Th2 cell populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507404A (ja) * 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法

Also Published As

Publication number Publication date
NO983372L (no) 1998-09-21
CZ293584B6 (cs) 2004-06-16
RU2186569C2 (ru) 2002-08-10
HUP9900681A2 (hu) 1999-07-28
CA2246162A1 (en) 1997-07-31
WO1997026883A1 (en) 1997-07-31
KR19990081930A (ko) 1999-11-15
KR100298158B1 (ko) 2001-09-06
NZ330784A (en) 1999-02-25
PL328003A1 (en) 1999-01-04
ATE216886T1 (de) 2002-05-15
AU1747897A (en) 1997-08-20
NO983372D0 (no) 1998-07-22
CZ232998A3 (cs) 1999-04-14
HUP9900681A3 (en) 1999-12-28
SI9720013A (sl) 1999-06-30
HU220105B (hu) 2001-10-28
PT879056E (pt) 2002-10-31
UA46815C2 (uk) 2002-06-17
CA2246162C (en) 2000-04-04
PL187439B1 (pl) 2004-07-30
DK0879056T3 (da) 2002-08-19
CN1209747A (zh) 1999-03-03
BR9707154A (pt) 1999-05-25
AU700642B2 (en) 1999-01-14
DE69712316T2 (de) 2003-01-02
EP0879056A1 (en) 1998-11-25
CN1190198C (zh) 2005-02-23
EP0879056A4 (en) 1999-01-13
SK100498A3 (en) 2001-03-12
DE69712316D1 (en) 2002-06-06
IL125088A0 (en) 1999-01-26
ES2172764T3 (es) 2002-10-01
EP0879056B1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
SK283342B6 (sk) Použitie ribavirínu na prípravu farmaceutického prostriedku
US6063772A (en) Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
Van Praag et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion
Lodi et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis
Wang et al. Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
Bailer et al. IL-13 and IFN-γ secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression
Fuchs et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans
Diamond et al. An essential contribution by IFN-γ to CD8+ T cell-mediated rejection of pancreatic islet allografts
Hashimoto et al. Modulation of Bcl-2 protein by CD4 cross-linking: a possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2
CZ55194A3 (en) Preparation for treating mammals infected by hepatitis c virus
Mohammadizad et al. TIM-3 as a marker of exhaustion in CD8+ T cells of active chronic hepatitis B patients
SE513429C2 (sv) Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
US20090130144A1 (en) Direct vaccination of the bone marrow
JP2008133293A (ja) 活性化ｔリンパ球におけるリバビリン及びリバビリン類似体によるｔｈ１型／ｔｈ２型サイトカインの発現の調節
US20030212015A1 (en) Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
Ank et al. Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2
Pedersen et al. Effects of isoprinosine treatment of HIV‐positive patients on blood mononuclear cell subsets, NK‐and T‐cell function, tumour necrosis factor, and interleukins 1, 2, and 6
ORLIKOWSKY et al. The cell surface marker phenotype of macrophages from HIV-1-infected subjects reflects an IL-10-enriched and IFN-γ-deprived donor environment
Yasukawa et al. Two Distinct Mechanisms of Cytotoxity Mediated by Herpes Simplex Virus-Specific CD4+ Human Cytotoxic T Cell Clones
AU700642C (en) Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated T-lymphocytes
Giraud et al. Plasmacytoid dendritic cell reconstitution following bone marrow transplantation: subnormal recovery and functional deficit of IFN-α/β production in response to herpes simplex virus
Bergamini et al. Ribavirin increases mitogen-and antigen-induced expression of CD40L on CD4+ T cells in vivo
Pérez‐Blas et al. Impaired T cell signal transduction through CD28 in a patient with idiopathic thrombocytopenia
Zamarchi et al. B and T cell function parameters during zidovudine treatment of human immunodeficiency virus-infected patients

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20100121